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Objectives The purpose of this study was to demonstrate the feasibility of percutaneous transvenous mitral valve-in-ring
(VIR) implantation using the Melody valve in an ovine model.
Background The recurrence of mitral regurgitation following surgical mitral valve (MV) repair in both adult and pediatric pa-
tients remains a significant clinical problem. Mitral annuloplasty rings are commonly used in MV repair proce-
dures and may serve as secure landing zones for percutaneous valves.
Methods Five sheep underwent surgical MV annuloplasty (24 mm, n  2; 26 mm, n  2; 28 mm, n  1). Animals under-
went cardiac catheterization with VIR implantation via a transfemoral venous, transatrial septal approach
1 week following surgery. Hemodynamic, angiographic, and echocardiographic data were recorded before and
after VIR.
Results VIR was technically successful and required 1 h of procedure time in all animals. Fluoroscopy demonstrated
securely positioned Melody valves within the annuloplasty ring in all animals. Angiography revealed no signifi-
cant MV regurgitation in 4 and moderate central MV regurgitation in the animal with the 28-mm annuloplasty.
All animals demonstrated vigorous left ventricular function, no outflow tract obstruction, and no aortic valve
insufficiency.
Conclusions This study demonstrated the feasibility of a purely percutaneous approach to MV replacement in patients with preex-
isting annuloplasty rings. This novel approach may be of particular benefit to patients with failed repair of ischemic
mitral regurgitation and in pediatric patients with complex structural heart disease. (J Am Coll Cardiol 2011;58:
2475–80) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.021Mitral valve (MV) repair with an annuloplasty device is the
preferred surgical therapy for mitral regurgitation (MR) (1).
Recent studies have called into question the durability of
MV repair for functional, degenerative, and congenital
etiologies (1–3).
The recurrence rate of significant MR after undersized
annuloplasty for ischemic MR approaches 30% 6 months
after surgery. Recent studies have documented the develop-
ment of recurrent MR after repair for degenerative etiolo-
gies to be 2% to 4% per year. Because of very complex
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2011, accepted September 5, 2011.pathologies, recurrence of MR following valve repair for
congenital anomalies is also common (4).
Recently the development of novel valve technologies has
made the percutaneous replacement of the aortic and
pulmonary valves possible (5–7). However, percutaneous
replacement of the MV is not currently possible because of
inherent anatomic features of the MV that make fixation
and perivalvular seal with currently available devices a
challenge. Recent clinical reports and animals studies have
demonstrated that the presence of a surgically placed annu-
loplasty device or a bioprosthetic valve makes MV replace-
ment with valved stents feasible. This technique has been
termed the valve-in-ring (VIR) or valve-in-valve (VIV)
procedure and has been performed surgically via transatrial
(8) and transapical (9–11) approaches using the Sapien
transcatheter heart valve (Edwards Lifesciences, Irvine,
California). Given the growing awareness of the limitations
of valve repair durability, VIR offers a potential remedial
procedure for high-risk adult and pediatric patients who
develop recurrent MR after MV repair.
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Melody Valve-in-Ring for Mitral Replacement December 6, 2011:2475–80In this study, we report on the
feasibility of performing VIR via
a completely percutaneous ap-
proach using the Melody trans-
catheter valve (Medtronic, Min-
neapolis, Minnesota) in a sheep
model of MV repair.
Methods
Surgical mitral annuloplasty.
Surgical MV annuloplasty was
performed on 5 sheep with CE-
Physio devices (24 mm, n  2; 26 mm, n  2; 28 mm, n  1;
Edwards Lifesciences) using standard techniques.
Melody VIR procedure. One week following surgery,
animals were brought to the catheterization laboratory for
the Melody VIR procedure. Vascular access was obtained in
the usual fashion. Under intracardiac echocardiographic
guidance, an atrial septal defect (ASD) was created. Next a
pre-shaped, super-stiff 0.035-inch guidewire (Lunderquist
wire, Cook Medical, Bloomington, Indiana) was introduced
and looped in the left ventricular (LV) apex (Figs. 1A and 1B),
reating a railway from the iliac vein to the LV via the ASD.
Melody valves were crimped onto 22-mm diameter an-
ioplasty balloons (22 mm  4 cm BIB balloon catheter,
uMed Inc., Hopington, New York). The crimped Melody
alve was advanced over the wire through the 22-F sheath
nd centered within the annuloplasty ring. Once in position,
he device was deployed via standard balloon inflation
echnique (Fig. 1B). Following deployment, the small ASD
as device closed (Helex, Gore Medical, Flagstaff, Ari-
ona). Post-deployment angiography was performed to
ssess valve position and function. Follow-up hemodynam-
cs and echocardiography were recorded and compared with
aseline values. Procedure time, defined as beginning after
ascular access was established and ending with ASD
losure, was recorded for all animals. After a period of
bservation (6 h), animals were euthanized. Necroscopy was
erformed, including gross inspection of the VIR complex.
ll experiments were approved by the University of Penn-
ylvania’s animal use committee.
tatistical analysis. Hemodynamic measurements before
nd after VIR were summarized using standard descriptive
tatistics and reported as mean  SD. Comparisons were
ade using paired student t test. Statistical significance was
efined as p  0.05.
esults
ll animals underwent successful surgical placement of an
nnuloplasty device.
The only significant difference between the pre- and
ost-VIR hemodynamic measures was an increased systolic
and mean) pulmonary artery (PA) pressure (33.8 3.7 mm Hg
s. 38  4.8 mm Hg; p  0.008) and a trend toward
Abbreviations
and Acronyms
ASD  atrial septal defect
LV  left ventricle/
ventricular
MR  mitral regurgitation
MV  mitral valve
PA  pulmonary artery
VIR  valve-in-ring
VIV  valve-in-valvencreased cardiac output (4.1  0.4 mm Hg vs. 5.2  0.9m Hg; p  0.06). Otherwise no significant differences
ere noted, as shown in Table 1. The greater and lesser
iameters of the “D-shaped” rings (Fig. 2) were recorded for
ll animals and are listed in Table 2. All VIR procedures
ere successful, and each required 1 h of procedure time
Table 2). Although engineered to be circular upon full
eployment, the Melody device conformed to the “D-
haped” annuloplasty ring in all cases (Fig. 2). Despite this
onformational change, the valves functioned well in the 24-
nd 26-mm rings. Follow-up angiography and echocardi-
Figure 1 Transvenous, Transseptal
Approach to Melody VIR Delivery
(A) The Melody device is crimped on the delivery balloon and advanced from
the femoral vein across the atrial septum and positioned centrally in the annu-
loplasty ring. (B) Deployment of the Melody valve via balloon inflation. (C) Fol-
low-up left ventriculogram. There is no mitral regurgitation and no left
ventricular (LV) outflow tract obstruction. A device was used to close the small
atrial septal defect (ASD). VIR  valve-in-ring.
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December 6, 2011:2475–80 Melody Valve-in-Ring for Mitral Replacementography revealed excellent LV systolic function. There was
MR through a central coaptation defect in 3 animals: trivial
to mild in 2 and moderate to severe in 1 (Fig. 3). In this
animal, the 28-mm annuloplasty ring appeared too large for
secure anchoring of the Melody device when it was ex-
panded to 22 mm. Therefore, this valve was expanded
beyond the listed maximum diameter to approximately 24
mm, resulting in malcoaptation of the valve leaflets and
moderate to severe central MR. There was no LV outflow
tract obstruction, aortic insufficiency, or perivalvular regur-
gitation in any animal (Table 1, Fig. 4).
Following euthanasia, necropsy demonstrated that all
Melody valves were anchored securely within the annulo-
plasty, with a tight seal formed between the Melody device
and the ring circumferentially (Fig. 5).
Hemodynamics*Table 1 Hemodynamics*
Variable
Before VIR
(n  5)
After VIR
(n  5) p Value
Aortic systolic pressure, mm Hg 98.8 11.8 93.0 5.8 0.44
Aortic diastolic pressure, mm Hg 60.4 7.9 52.4 11.1 0.25
Mean aortic pressure, mm Hg 73.6 9.7 65.4 5.9 0.23
Heart rate, beats/min 99.2 16.8 97.8 18.9 0.64
LV systolic pressure, mm Hg 100.4 12.8 97.0 8.3 0.64
LV diastolic pressure, mm Hg 11.2 2.6 10.8 2.4 0.65
Mean LA pressure, mm Hg 17.0 4.0 17.8 2.6 0.55
Mean PCWp, mm Hg 16.2 2.9 16.8 2.8 0.67
PA systolic pressure, mm Hg 33.8 3.7 38.0 4.8 0.008
PA diastolic pressure, mm Hg 19.6 3.1 20.8 4.0 0.21
Mean PA pressure, mm Hg 24.8 1.9 28.0 3.0 0.02
Mean RA pressure, mm Hg 7.6 2.5 10.2 1.5 0.07
Cardiac output, l/min 4.1 0.4 5.2 0.9 0.06
*There were no significant differences between the hemodynamics measured before surgical
annuloplasty ring placement and after valve-in-ring (VIR) placement.
LA left atrial; LV left ventricular; PA pulmonary artery; PCWp pulmonary capillary wedge
pressure; PVR  pulmonary vascular resistance; RA  right atrial; RV  right ventricular.
Figure 2 En Face View, Pre- and Post-Melody VIR Procedure
The Melody device conformed to the “D shape” of the annuloplasty ring upon valvDiscussion
In this report, we described the first transvenous, transa-
trial, septal VIR implantation using the Melody device.
Via standard vascular access and transseptal techniques,
we successfully deployed the Melody valve into the mitral
position from the venous circulation in all animals,
without difficulty or complication. The Melody valves
were securely seated in all cases. Importantly, although
there was a conformational change noted in the Melody
valves from “round” to “oval” or “D-shaped” when im-
planted into the annuloplasty rings, there was no peri-
valvular leakage and only trivial to mild central MR
(except in the 1 animal in which we intentionally over-
sized the device) (Fig. 4). The only significant hemody-
namic change noted following VIR was an increase in PA
pressure (p  0.008). The exact cause of this difference is
unclear; however, it was likely due to a trend toward
increased cardiac output secondary to sympathetic up-
regulation (p  0.06) after VIR. Theoretically, increased
PA pressure could also be secondary to pulmonary vein
obstruction or an increase in left atrial pressure caused by
MR and/or mitral stenosis. However, the pulmonary
veins were unobstructed, and the mean left atrial pressure
did not increase following VIR (p  0.55). The success
and relative ease of this procedure highlighted the po-
tential for this approach in patients with ongoing MV
dysfunction despite prior surgical repair.
Irrespective of the cause, surgical repair of systemic
atrioventricular valve regurgitation (mitral, common atrio-
ventricular, or tricuspid valves) carries a significant risk for
recurrence in both adult and pediatric patients (4,12).
Despite this risk, in most circumstances, valve repair is still
preferred over replacement, due to durability concerns
associated with tissue valves and to the reduced need for
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Melody Valve-in-Ring for Mitral Replacement December 6, 2011:2475–80systemic anticoagulation when compared with mechanical
valves (13). In the last decade, the advent of percutaneous
valve replacement has resulted in new minimally invasive
therapeutic options for patients with dysfunctional aortic
and pulmonary valves (5–7). Although many promising
percutaneous MV repair technologies have been developed
(2,14), percutaneous MV replacement with a single device
remains elusive. The inherent anatomic features of the MV
make fixation and perivalvular seal a troublesome challenge.
In particular, the mitral annulus lacks a uniform “landing
zone” for secure deployment of a percutaneous device.
Despite these challenges, promising steps toward 1-stage
percutaneous MV replacement are being made (15,16). In
the meantime, minimally invasive surgical MV replacement
via VIV and more recently VIR procedures have been
Procedural VariablesTable 2 Procedural Variables
1
Weight, kg 39
Nominal annuloplasty ring size, mm* 24
Greater ring dimension (largest diameter), mm† 22
Lesser ring dimension (shortest diameter), mm† 17.9
Melody valve size, mm 22
MR grade before VIR (ECHO 1–4) 0
MR grade after VIR (ECHO 0–4) 1(central coaptation)§
MR grade (angiography 0–4) 0
ASD size, mm 7
ASD device size (Helex), mm 20
Procedure time, min¶ 60
*Size as listed by the manufacturer (Edwards Lifesciences, Irvine, California). †Given the “D” or “ov
to be considered when sizing for Melody valve implant. ‡This valve was deployed on a 22-mm ba
had residual mitral regurgitation (MR), although it was significant only in animal 5 in which the Melo
a central coaptation defect in the Melody valve in all animals (Fig. 3). There were no perivalvular
imaging with color flow. The maximum diameters are listed. ¶For the purposes of this study, proc
implantation and ASD closure.
Abbreviations as in Table 1.
Figure 3 Doppler Echocardiography Following Melody VIR Proc
Three of the 5 animals had residual mitral regurgitation (MR) following the valve-in
moderate to severe for 1 animal (animal 5) (C), in which a 28-mm annuloplasty ri
mechanism of MR was via a central coaptation defect in the Melody device in all adescribed in which the Edwards Sapien device was deployed
into previously placed bioprosthetic tissue valves (9,10)
nd/or annuloplasty rings (8,11) via a surgical transapical or
ransatrial approach. These procedures are intended to
xtend the functional life of the surgical valve in a manner
nalogous to Melody and Sapien valve treatment for dys-
unctional surgical conduits in the pulmonary position. The
IR and VIV procedures have the potential to change the
ay in which MV patients are managed, especially as
ercutaneous valve technologies undergo further refine-
ents that optimize their performance in these new set-
ings.
tudy limitations. The Melody valves used in this experi-
ent were previously handled and cosmetically flawed, thus
ot viable for commercial use and not optimal for functionality
Animal
2 3 4 5
48 52 63 43
24 26 26 28
22.7 24.4 24 25
16.3 16.4 17.3 19.6
22 22 22 22‡
0 2 0 3
0 0 2(central coaptation)§ 3(central coaptation)§
0 0 0 3
9 8 8 8
20 20 20 20
50 55 45 50
pe of the annuloplasty ring, there are greater and lesser diameters (as measured fluoroscopically)
t post-dilated to 24 mm to ensure secure anchoring in the 28-mm ring. §Three of the 5 animals
e was oversized to fit securely in the 28-mm annuloplasty ring. The mechanism of MR was through
oted. Atrial septal defect (ASD) diameter was determined using intracardiac echocardiographic
me was defined as beginning after vascular access was established and ending after Melody VIR
IR) procedure. The ECHO grade was trivial to mild for 2 animals (A and B) and
used, requiring “overdilation” of the Melody valve for secure anchoring. The
s as shown above. There were no perivalvular leaks.al” sha
lloon bu
dy valv
leaks n
edure tiedure
-ring (V
ng was
nimal
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December 6, 2011:2475–80 Melody Valve-in-Ring for Mitral Replacementtesting. Furthermore, these devices are engineered for implan-
tation into the pulmonary circulation. They are undersized
relative to the normal adult mitral annulus (maximum func-
tional diameter 22 mm) and are not intended for use in the
systemic circulation, where the afterload is generally much
higher. Despite these limitations, these results were a proof of
concept sufficient to demonstrate the feasibility of the trans-
venous VIR procedure.
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Figure 4 Left Ventriculogram and Aortogram Status After Melo
There is no left ventricular outflow tract obstruction (LVOTO) and no aortic valve in
Figure 5 Necropsy
In all animals, the Melody device was securely anchored within the annuloplasty ri
The figure shows representative views from the left atrial and left ventricular sidesREFERENCES
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